Good question. I think we'd be in a lot of pain if they pulled guidance completely or revised it down. We'd be stuck in a lower share price range and our NNZ-2591 progress won't help move the SP much. If NNZ-2591 goes well, we'd get a similar back ended re-rate, but many investors wouldn't want to wait around that long (to phase 3 for PMS) so the SP would probably suffer in the short-medium term.
So far (outside of the share price) everything Neuren and Acadia has publicly announced has been positive to at least meeting guidance. I think being on track to meeting guidance (even if on the lower end) will be considered a decent result given where the SP's are for NEU and ACAD.
Good question. I think we'd be in a lot of pain if they pulled...
-
- There are more pages in this discussion • 239 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.32 |
Change
1.045(8.52%) |
Mkt cap ! $1.699B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.39 | $12.79 | $8.740M | 667.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 234 | $13.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.32 | 1977 | 10 |
View Market Depth
| Last trade - 15.58pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |